K284-6111 prevents the amyloid beta-induced neuroinflammation and impairment of recognition memory through inhibition of NF-κB-mediated CHI3L1 expression.

BACKGROUND: Alzheimer's disease, which is pathologically characterized by an excessive accumulation of amyloid beta (Aß) fibrils, is a degenerative brain disease and the most common cause of dementia. In a previous study, it was reported that an increased level of CHI3L1 in plasma was found in AD patients. We investigated the inhibitory effect of 2-({3-[2-(1-cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}sulfanyl)-N-(4-ethylphenyl)butanamide (K284-6111), an inhibitor of chitinase 3 like 1 (CHI3L1), on memory impairment in Aß1-42-infused mice, and microglial BV-2 cells and astrocytes. METHODS: We examined whether K284-6111 (3 mg/kg given orally for 4 weeks) prevents amyloidogenesis and memory loss in Aß1-42-induced AD mice model. After intracerebroventrical (ICV) infusion of Aß1-42 for 14 days, the cognitive function was assessed by the Morris water maze test and passive avoidance test. K284-6111 treatment was found to reduce Aß1-42-induced memory loss. RESULTS: A memory recovery effect was found to be associated with the reduction of Aß1-42-induced expression of inflammatory proteins (iNOS, COX-2, GFAP, and Iba-1) and the suppression of CHI3L1 expression in the brain. Additionally, K284-6111 reduced Aß1-42-induced ß-secretase activity and Aß generation. Lipopolysaccharide (LPS)-induced (1 µg/mL) expression of inflammatory (COX-2, iNOS, GFAP, Iba-1) and amyloidogenic proteins (APP, BACE1) were decreased in microglial BV-2 cells and cultured astrocytes by the K284-6111 treatment (0.5, 1, and 2 µM). Moreover, K284-6111 treatment suppressed p50 and p65 translocation into the nucleus, and phosphorylation of IκB in vivo and in vitro. CONCLUSION: These results suggest that CHI3L1 inhibitor could be an applicable intervention drug in amyloidogenesis and neuroinflammation, thereby preventing memory dysfunction via inhibition of NF-κB.

Cognition-enhancing and neuroprotective effects of hederacolchiside-E from Pulsatilla koreana.

The root extract of Pulsatilla koreana (Ranunculaceae) has been found to have prominent abilities to reverse scopolamine-induced cognitive impairment in rats, and to increase the viability of human neuroblastoma SK-N-SH cells incubated with amyloid-beta peptide (1 - 42) [A beta (1 - 42)]. In vivo and in vitro activity-guided fractionation studies using solvent-partitioning and subsequent chromatographic separations led to the isolation of hederacolchiside-E, an oleanolic glycoside, as an active ingredient. Administration of hederacolchiside-E (30 and 60 mg/kg body weight, P. O.) increased the step-through latency time in the passive avoidance test as efficiently as tacrine (30 mg/kg, P. O.). The neuroprotective effect of hederacolchiside-E on SK-N-SH cells against the toxicity of A beta (1 - 42) was comparable to that of catechin. These data suggest that hederacolchiside-E might be a good therapeutic candidate for the treatment of Alzheimer's disease.

Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.

The pharmacokinetics of oleanolic acid was evaluated in vitro and in vivo. From Caco-2 cell permeation studies, oleanolic acid was a low permeability compound with no directional effects, suggesting a low in vivo absorption mediated by a passive diffusion. Oleanolic acid was metabolically unstable following incubation with rat liver microsomes in the presence of NADPH. After intravenous injection at doses of 0.5, 1 and 2 mg/kg doses, oleanolic acid showed dose-linear pharmacokinetics as evidenced by unaltered CL (28.6-33.0 ml/min/kg), Vss (437-583 ml/kg), dose-normalized AUC (16.0-17.9 microg min/ml based on 1 mg/kg) and t1/2 (41.9-52.7 min). Following oral administration of oleanolic acid at doses of 10, 25 and 50 mg/kg, Tmax, t1/2, dose-normalized Cmax (66-74 ng/ml based on 25 mg/kg) and dose-normalized AUC (5.4-5.9 microg min/ml based on 25 mg/kg) were comparable between 25 and 50 mg/kg dose, but the plasma concentrations at 10 mg/kg dose were not measurable as they were below the limit of quantitation (2 ng/ml). The absolute oral bioavailability was 0.7% for oral doses of 25 and 50 mg/kg. The extent of urinary excretion was minimal for both i.v. and oral doses. The very low oral bioavailability of oleanolic acid could be due to a poor absorption and extensive metabolic clearance.